Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results from a randomised non-inferiority phase 3 trial

The Lancet Oncology

Volumn 16, Issue 3, 2015, Pages 274-283

  Aluwini, Shafak ^a   Pos, Floris ^b   Schimmel, Erik ^c   van Lin, Emile ^d   Krol, Stijn ^e   van der Toorn, Peter Paul ^f   de Jager, Hanja ^g   Dirkx, Maarten ^a   Alemayehu, Wendimagegn Ghidey ^a   Heijmen, Ben ^a   Incrocci, Luca ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c Institute for Radiation Oncology Arnhem   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f CATHARINA HOSPITAL   (Netherlands)

^g Radiotherapy Center West   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; CONVENTIONALLY FRACTIONATED RADIOTHERAPY; DISEASE SEVERITY; GASTROINTESTINAL TOXICITY; GENITOURINARY TOXICITY; HORMONAL THERAPY; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; TOXICITY; UROGENITAL TRACT DISEASE; WORLD HEALTH ORGANIZATION; ACUTE DISEASE; ADVERSE EFFECTS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; GASTROINTESTINAL DISEASES; INTENTION TO TREAT ANALYSIS; MALE UROGENITAL DISEASES; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROSTATIC NEOPLASMS; QUESTIONNAIRE; RADIATION INJURIES; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; GASTROINTESTINAL DISEASES; HUMANS; INCIDENCE; INTENTION TO TREAT ANALYSIS; MALE; MALE UROGENITAL DISEASES; MIDDLE AGED; NETHERLANDS; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RADIATION INJURIES; RADIOTHERAPY; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924955384     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70482-6     Document Type: Article

References (32)

1. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012, 61:1079-1092.
2. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
3. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1990-1996.
4. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
5. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005, 61:1019-1034.
6. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52:6-13.
7. Dale RG, Jones B Is the alpha/beta for prostate tumors really low? In regard to Fowler et al., IJROBP 2001;50:1021-1031. Int J Radiat Oncol Biol Phys 2002, 52:1427-1428.
8. Fowler JF The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005, 44:265-276.
9. Arcangeli G, Fowler J, Gomellini S, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 79:1013-1021.
10. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005, 63:1463-1468.
11. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23:6132-6138.
12. Martin JM, Rosewall T, Bayley A, et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007, 69:1084-1089.
13. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59:380-385.
14. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001, 58:843-848.
15. Vargas CE, Galalae R, Demanes J, et al. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Int J Radiat Oncol Biol Phys 2005, 63:1474-1482.
16. van Andel G, Bottomley A, Fossa SD, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008, 44:2418-2424.
17. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997, 49:822-823.
18. Cox JD, Stetz J, Pajak TF Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31:1341-1346.
19. Peeters ST, Lebesque JV, Heemsbergen WD, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2006, 64:1151-1161.
20. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ, Group C Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006, 295:1152-1160.
21. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 68:1424-1430.
22. Bekelman JE, Mitra N, Efstathiou J, et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81:e325-e334.
23. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010, 76:S3-S9.
24. Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2010, 14:1-108.
25. Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 84:125-129.
26. Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. Proc Am Soc Clin Oncol 2013, 31(suppl). (abstr) 3860.
27. Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13:43-54.
28. Coote JH, Wylie JP, Cowan RA, Logue JP, Swindell R, Livsey JE Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity. Int J Radiat Oncol Biol Phys 2009, 74:1121-1127.
29. Peeters ST, Hoogeman MS, Heemsbergen WD, et al. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2005, 63:1142-1152.
30. Goldner G, Wachter-Gerstner N, Wachter S, Dieckmann K, Janda M, Potter R Acute side effects during 3-D-planned conformal radiotherapy of prostate cancer. Differences between patient's self-reported questionnaire and the corresponding doctor's report. Strahlenther Onkol 2003, 179:320-327.
31. Valdagni R, Rancati T, Fiorino C, et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol 2008, 71:1065-1073.
32. Arcangeli S, Strigari L, Soete G, et al. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. Int J Radiat Oncol Biol Phys 2009, 73:39-45.